CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas

CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions

(2019) Bradley D Hunter et al.   JNCI-Journal of the National Cancer Institute

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

(2019) Dinh-Toi Chu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).

(2019) Surbhi Sidana et al.   JOURNAL OF CLINICAL ONCOLOGY

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

(2019) Chelsea Kotch et al.   Expert Review of Clinical Immunology

Axicabtagene Ciloleucel, an Anti‐CD19 Chimeric Antigen Receptor T‐Cell Therapy for Relapsed or Refractory Large B‐Cell Lymphoma: Practical Implications for the Community Oncologist

(2019) Caron A. Jacobson et al.   ONCOLOGIST

Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial

(2019) Theodore W Laetsch et al.   LANCET ONCOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Cancer immunotherapy with CAR-T cells – behold the future

(2018) Charlotte Graham et al.   CLINICAL MEDICINE

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia

(2018) Stephanie Vairy et al.   Drug Design Development and Therapy

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

(2017) James N. Kochenderfer et al.   MOLECULAR THERAPY

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

(2016) Jae H. Park et al.   BLOOD

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

CAR models: next-generation CAR modifications for enhanced T-cell function

(2016) Daniel Abate-Daga et al.   Molecular Therapy-Oncolytics

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY